MIDDLEWAY SURGERY
MIDDLEWAY, ST. BLAZEY, PAR
HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2010 | 12 | 14 | 85.7% | |
| HF 4 | 2011 | 10 | 12 | 83.3% | |
| HF 4 | 2012 | 15 | 18 | 83.3% | |
| HF 4 | 2013 | 20 | 25 | 80.0% | |
| HF004 | 2014 | 21 | 25 | 84.0% | |
| HF004 | 2015 | 21 | 24 | 87.5% | |
| HF004 | 2016 | 21 | 25 | 84.0% | |
| HF004 | 2017 | 20 | 25 | 80.0% | |
| HF004 | 2018 | 18 | 18 | 100.0% | |
| HF004 | 2020 | 21 | 22 | 95.5% | |
| HF006 | 2021 | 28 | 35 | 80.0% | |
| HF006 | 2022 | 31 | 32 | 96.9% | |
| HF006 | 2023 | 51 | 54 | 94.4% |
